British bil­lion­aire Jim Mel­lon and high-pro­file part­ners roll the dice on an an­ti-ag­ing up­start

When British bil­lion­aire Jim Mel­lon wants to map out an in­vest­ment strat­e­gy, he likes to write a book first. Out of that process came his most re­cent work — Ju­ve­nes­cence: In­vest­ing in the Age of Longevi­ty. Now he and some close as­so­ciates with some of the best con­nec­tions in biotech are us­ing the book as in­spi­ra­tion to launch a new com­pa­ny — al­so named Ju­ve­nes­cence — with plans to make a big splash in an­ti-ag­ing re­search.

Jim Mel­lon

And they’re plant­i­ng the first seeds now with a new joint ven­ture that will start to lay the foun­da­tion for the pipeline with ar­ti­fi­cial in­tel­li­gence tech­nol­o­gy.

“We are at an in­flec­tion point for the treat­ment of ag­ing,” says Greg Bai­ley, who likes to high­light some of the new cel­lu­lar path­ways that are point­ing to new ther­a­pies that can counter the ef­fects of ag­ing.

“I think this is go­ing to be the biggest deal I’ve ever done,” Bai­ley tells me in a phone in­ter­view, as his plane was prepar­ing for a take­off.  “It will need repet­i­tive fi­nanc­ing.  Five to $600 mil­lion was raised for Medi­va­tion. As we hit in­flec­tion points, we will need to raise a dra­mat­ic amount of mon­ey.”

Gre­go­ry Bai­ley

Bai­ley, the CEO of Ju­ve­nes­cence, was one of the ear­ly back­ers of Medi­va­tion, where he was a board di­rec­tor for 7 years — be­fore Pfiz­er stepped in to buy the biotech for $14 bil­lion. More re­cent­ly, he helped po­si­tion Bio­haven for an IPO, as­sem­bling a pipeline that in­cludes a late-stage drug in-li­censed from Bris­tol-My­ers Squibb be­fore rais­ing $190 mil­lion a few months ago in their maid­en of­fer­ing. The chair­man at Bio­haven is his long­time col­league De­clan Doogan, a for­mer top Pfiz­er re­search ex­ec who is com­ing in as a prin­ci­pal to the new ven­ture along­side Mel­lon and Bai­ley.

The pri­ma­ry game plan at Ju­ve­nes­cence, ex­plains Bai­ley, is to come up with var­i­ous op­er­a­tions en­gaged in de­vel­op­ing new an­ti-ag­ing drugs. Ju­ve­nes­cence AI is a joint ven­ture they’ve just set up with Alex Zha­voronkov, who runs In­sil­i­co Med­i­cine, based in Bal­ti­more. Mel­lon met Zha­voronkov while he was re­search­ing his book, says Bai­ley, and be­lieves that the tech the sci­en­tist de­vel­oped can il­lu­mi­nate new pro­grams with a bet­ter chance of suc­cess.

“They are go­ing to take up to 5 mol­e­cules from us every year for de­vel­op­ment,” says Zha­voronkov, an en­thu­si­as­tic ad­vo­cate of AI in drug re­search who’s al­so been work­ing on some al­liances with Big Phar­ma play­ers. The group has in­vest­ed about $7 mil­lion in the tech­nol­o­gy so far, he says, get­ting the JV set up. More will fol­low.

Alex Zha­voronkov

“We can gen­er­ate mol­e­cules with spe­cif­ic mol­e­c­u­lar prop­er­ties,” adds Zha­voronkov, who al­so has a spe­cial fo­cus on an­ti-ag­ing re­search.

“The mas­sive lib­er­a­tion of new da­ta needs to trans­form in­to knowl­edge,” says Doogan. “AI is the buzz word; can we take in­cre­men­tal steps, in an it­er­a­tive learn­ing process, cap­ture all knowl­edge?”

Ju­ve­nes­cence Bio will be charged with build­ing the pipeline, says Bai­ley, in part with the mol­e­cules that will be iden­ti­fied through the AI ven­ture. And Doogan will play a lead role in or­ga­niz­ing the team now, much as he was cred­it­ed with at Bio­haven.

Aside from the cel­lu­lar path­ways that have at­tract­ed their at­ten­tion, the biotech will look to ef­fect change in the mi­to­chon­dria, the cell’s pow­er­house, as well as clean up senes­cent cells that ac­cu­mu­late as the body grows old­er. And Bai­ley ex­pects he’ll be work­ing some Bio­haven-like deals to de­vel­op an ad­vanced pipeline at a rapid pace.

The prin­ci­pals chipped in the seed mil­lions for the com­pa­ny and in­vest­ed in the JV with Zha­voronkov. Bai­ley says you can ex­pect to see $20 mil­lion to $50 mil­lion more from a friends-and-fam­i­ly raise be­fore the end of the year. And it’s ex­pect­ed to grow from there.

De­clan Doogan

Doogan plans to re­cruit var­i­ous team lead­ers, in­di­vid­u­als who will be in charge of spe­cif­ic projects with 10 or few­er peo­ple on the crew. Like any biotech, he notes, they plan to re­ly on a se­mi-vir­tu­al struc­ture, with a ma­jor amount of out­sourc­ing in place of staff.

The biotech won’t just be a biotech, says Doogan. It will cov­er “mul­ti­ple do­mains: di­ag­nos­tics, con­sumer, con­ven­tion­al drug de­vel­op­ment — broad ideas to en­gage the con­sumer.”

The key, he says, is fo­cus­ing on not just a longer life, but a bet­ter one.

“Not just longer, but bet­ter longer,” is the way Doogan puts it. “Healthy ag­ing is the ob­jec­tive here.”

That leaves a lot of room.

“There are 52 ways to drop blood pres­sure, but we’ve done noth­ing for os­teoarthri­tis,” says Doogan by way of ex­am­ple.

“We have to be re­al­ly clever,” says Bai­ley. Drugs like No­var­tis’ mTOR in­hibitor everolimus, which con­trols cell growth and pro­lif­er­a­tion, can be a mod­el. Os­teoarthri­tis, a dis­ease as­so­ci­at­ed with ag­ing, can be the kind of dis­ease fo­cus that can dri­ve ear­ly work.

It’s ear­ly days yet for an­ti-ag­ing drug re­search. A few stal­warts like Bob Nelsen at Arch have backed the first few star­tups in the field. But Mel­lon and his col­leagues say now’s the time.

The longevi­ty in­dus­try, Mel­lon said re­cent­ly, is des­tined to grow “in­to the world’s largest in­dus­try.”

And he wants in.

Chas­ing Roche's ag­ing block­buster fran­chise, Am­gen/Al­ler­gan roll out Avastin, Her­ceptin knock­offs at dis­count

Let the long battle for biosimilars in the cancer space begin.

Amgen has launched its Avastin and Herceptin copycats — licensed from the predecessors of Allergan — almost two years after the FDA had stamped its approval on Mvasi (bevacizumab-awwb) and three months after the Kanjinti OK (trastuzumab-anns). While the biotech had been fielding biosimilars in Europe, this marks their first foray in the US — and the first oncology biosimilars in the country.

Seer adds ex-FDA chief Mark Mc­Clel­lan to the board; Her­cules Cap­i­tal makes it of­fi­cial for new CEO Scott Bluestein

→ On the same day it announced a $17.5 million Series C, life sciences and health data company Seer unveiled that it had lured former FDA commissioner and ex-CMS administrator Mark McClellan on to its board. “Mark’s deep understanding of the health care ecosystem and visionary insights on policy reform will be crucial in informing our thinking as we work to bring our liquid biopsy and life sciences products to market,” said Seer chief and founder Omid Farokhzad in a statement.

Norbert Bischofberger. Kronos

Backed by some of the biggest names in biotech, Nor­bert Bischof­berg­er gets his megaround for plat­form tech out of MIT

A little over a year ago when I reported on Norbert Bischofberger’s jump from the CSO job at giant Gilead to a tiny upstart called Kronos, I noted that with his connections in biotech finance, that $18 million launch round he was starting off with could just as easily have been $100 million or more.

With his first anniversary now behind him, Bischofberger has that mega-round in the bank.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,000+ biopharma pros reading Endpoints daily — and it's free.

Francesco De Rubertis

Medicxi is rolling out its biggest fund ever to back Eu­rope's top 'sci­en­tists with strange ideas'

Francesco De Rubertis built Medicxi to be the kind of biotech venture player he would have liked to have known back when he was a full time scientist.

“When I was a scientist 20 years ago I would have loved Medicxi,’ the co-founder tells me. It’s the kind of place run by and for investigators, what the Medicxi partner calls “scientists with strange ideas — a platform for the drug hunter and scientific entrepreneur. That’s what I wanted when I was a scientist.”

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,000+ biopharma pros reading Endpoints daily — and it's free.

Af­ter a decade, Vi­iV CSO John Pot­tage says it's time to step down — and he's hand­ing the job to long­time col­league Kim Smith

ViiV Healthcare has always been something unique in the global drug industry.

Owned by GlaxoSmithKline and Pfizer — with GSK in the lead as majority owner — it was created 10 years ago in a time of deep turmoil for the field as something independent of the pharma giants, but with access to lots of infrastructural support on demand. While R&D at the mother ship inside GSK was souring, a razor-focused ViiV provided a rare bright spot, challenging Gilead on a lucrative front in delivering new combinations that require fewer therapies with a more easily tolerated regimen.

They kept a massive number of people alive who would otherwise have been facing a death sentence. And they made money.

And throughout, John Pottage has been the chief scientific and chief medical officer.

Until now.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,000+ biopharma pros reading Endpoints daily — and it's free.

Daniel O'Day

No­var­tis hands off 3 pre­clin­i­cal pro­grams to the an­tivi­ral R&D mas­ters at Gilead

Gilead CEO Daniel O’Day’s new task hunting up a CSO for the company isn’t stopping the industry’s dominant antiviral player from doing pipeline deals.

The big biotech today snapped up 3 preclinical antiviral programs from pharma giant Novartis, with drugs promising to treat human rhinovirus, influenza and herpes viruses. We don’t know what the upfront is, but the back end has $291 million in milestones baked in.

Vas Narasimhan, AP Images

On a hot streak, No­var­tis ex­ecs run the odds on their two most im­por­tant PhI­II read­outs. Which is 0.01% more like­ly to suc­ceed?

Novartis CEO Vas Narasimhan is living in the sweet spot right now.

The numbers are running a bit better than expected, the pipeline — which he assembled as development chief — is performing and the stock popped more than 4% on Thursday as the executive team ran through their assessment of Q2 performance.

Year-to-date the stock is up 28%, so the investors will be beaming. Anyone looking for chinks in their armor — and there are plenty giving it a shot — right now focus on payer acceptance of their $2.1 million gene therapy Zolgensma, where it’s early days. And CAR-T continues to underperform, but Novartis doesn’t appear to be suffering from it.

So what could go wrong?

Actually, not much. But Tim Anderson at Wolfe pressed Narasimhan and his development chief John Tsai to pick which of two looming Phase III readouts with blockbuster implication had the better odds of success.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,000+ biopharma pros reading Endpoints daily — and it's free.

On a glob­al romp, Boehringer BD team picks up its third R&D al­liance for Ju­ly — this time fo­cused on IPF with $50M up­front

Boehringer Ingelheim’s BD team is on a global deal spree. The German pharma company just wrapped its third deal in 3 weeks, going back to Korea for its latest pipeline pact — this time focused on idiopathic pulmonary fibrosis.

They’re handing over $50 million to get their hands on BBT-877, an ATX inhibitor from Korea’s Bridge Biotherapeutics that was on display at a science conference in Dallas recently. There’s not a whole lot of data to evaluate the prospects here.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,000+ biopharma pros reading Endpoints daily — and it's free.

Servi­er scoots out of an­oth­er col­lab­o­ra­tion with Macro­Gen­ics, writ­ing off their $40M

Servier is walking out on a partnership with MacroGenics $MGNX — for the second time.

After the market closed on Wednesday MacroGenics put out word that Servier is severing a deal — inked close to 7 years ago — to collaborate on the development of flotetuzumab and other Dual-Affinity Re-Targeting (DART) drugs in its pipeline.

MacroGenics CEO Scott Koenig shrugged off the departure of Servier, which paid $20 million to kick off the alliance and $20 million to option flotetuzumab — putting a heavily back-ended $1 billion-plus in additional biobuck money on the table for the anti-CD123/CD3 bispecific and its companion therapies.